| Comment on"'Stemness': transcriptional profiling of embryonic and adult stem cells" and" a stem cell molecular signature"(I) NO Fortunel, HH Otu, HH Ng, J Chen, X Mu, T Chevassut, X Li, M Joseph, ... Science 302 (5644), 393-393, 2003 | 481 | 2003 |
| Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells M Jackson, A Krassowska, N Gilbert, T Chevassut, L Forrester, J Ansell, ... Molecular and cellular biology 24 (20), 8862-8871, 2004 | 407 | 2004 |
| Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma CI Jones, MV Zabolotskaya, AJ King, HJS Stewart, GA Horne, ... British journal of cancer 107 (12), 1987-1996, 2012 | 162 | 2012 |
| Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? EE Ladikou, H Sivaloganathan, KM Milne, WE Arter, R Ramasamy, ... Clinical Medicine 20 (5), e178, 2020 | 141 | 2020 |
| Doubts concerning the recently reported human neutrophil lifespan of 5.4 days PS Tofts, T Chevassut, M Cutajar, NG Dowell, AM Peters Blood, The Journal of the American Society of Hematology 117 (22), 6050-6052, 2011 | 130 | 2011 |
| DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia RE Rau, BA Rodriguez, M Luo, M Jeong, A Rosen, JH Rogers, ... Blood, The Journal of the American Society of Hematology 128 (7), 971-981, 2016 | 128 | 2016 |
| The epigenetic landscape of acute myeloid leukemia E Conway O’Brien, S Prideaux, T Chevassut Advances in hematology 2014, 2014 | 123 | 2014 |
| The genetic architecture of multiple myeloma SM Prideaux, E Conway O'Brien, TJ Chevassut Advances in hematology 2014, 2014 | 120 | 2014 |
| BRD 4 associates with p53 in DNMT 3A‐mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ 1 HJS Stewart, GA Horne, S Bastow, TJT Chevassut Cancer medicine 2 (6), 826-835, 2013 | 105 | 2013 |
| RETRACTED: Autoimmunity as the Consequence of a Spontaneous Mutation in Rasgrp1 K Layer, G Lin, A Nencioni, W Hu, A Schmucker, AN Antov, X Li, ... Immunity 19 (2), 243-255, 2003 | 93 | 2003 |
| Thrombotic risk in COVID-19: a case series and case–control study SM Stoneham, KM Milne, E Nuttall, GH Frew, BRH Sturrock, ... Clinical Medicine 20 (4), e76, 2020 | 85 | 2020 |
| COVID‐19 mortality in patients on anticoagulants and antiplatelet agents H Sivaloganathan, EE Ladikou, T Chevassut British journal of haematology 190 (4), e192, 2020 | 84 | 2020 |
| Genomic landscapes and clonality of de novo AML CA Miller, RK Wilson, TJ Ley The New England journal of medicine 369 (15), 1473, 2013 | 82 | 2013 |
| The 3'to 5'exoribonuclease DIS3: from structure and mechanisms to biological functions and role in human disease SR Robinson, AW Oliver, TJ Chevassut, SF Newbury Biomolecules 5 (3), 1515-1539, 2015 | 63 | 2015 |
| Haematology patients and the internet–The use of on-line health information and the impact on the patient–doctor relationship T Rider, M Malik, T Chevassut Patient education and counseling 97 (2), 223-238, 2014 | 62 | 2014 |
| Targeting SHP-1, 2 and SHIP pathways: a novel strategy for cancer treatment? W Dempke, P Uciechowski, K Fenchel, T Chevassut Oncology 95 (5), 257-269, 2018 | 61 | 2018 |
| Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1 GA Horne, HJS Stewart, J Dickson, S Knapp, B Ramsahoye, T Chevassut Stem Cells and Development 24 (7), 879-891, 2015 | 61 | 2015 |
| Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia EE Ladikou, H Sivaloganathan, A Pepper, T Chevassut Current oncology reports 22, 1-9, 2020 | 57 | 2020 |
| Clonal hematopoiesis and atherosclerosis R Phillips, S Chaudry, T Chevassut The New England journal of medicine 377 (14), 1401, 2017 | 56 | 2017 |
| Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis SF Chaudry, TJT Chevassut BioMed research international 2017, 2017 | 52 | 2017 |
